Pending Recruitment

2020-05-21T08:45:11+00:00May 21st, 2020|Clinical Studies|

Share this article

Facebook Twitter

Newsletter

Leave this field empty if you're human:

Latest News

3rd Consortium Meeting (Online)
September 25, 2020
WP4 LOI accepted by the FDA!
April 8, 2020
2nd Consortium Meeting
September 1, 2019

Twitter

Tweets by @IMITransBioLine

ABOUT IMI

The Innovative Medicines Initiative is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It is working to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need. It works by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is the world's biggest public-private partnership (PPP) in the life sciences.

Subscribe to our Newsletter

Leave this field empty if you're human:

ACKNOWLEDGEMENT

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 821283. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA companies.

IMI Europa

info@transbioline.com

© Copyright | TransBioLine | Disclaimer: The TransBioLine website reflects the author’s view and that neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained therein.

Facebook Twitter Instagram

This website uses cookies and third party services. Ok